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Adjuvant breast radiation therapy after breast conservation surgery is recommended as it yields signiﬁcant reduction in the risk of
local recurrence, and confers a potential overall survival beneﬁt. Although the standard breast radiation regimen has historically
beendeliveredover5–7weeks;morenovel,shortercoursesofbreastradiationarecurrentlybeingemployed,oﬀeringtheadvantage
of more convenience and less time-commitment. Herein, we review the recent literature substantiating these abbreviated radiation
treatment approaches and the methods of delivery thereof. In addition, we discuss imaged guided techniques currently being
utilized to further reﬁne the delivery of adjuvant breast radiation therapy.
1.Introduction
Multiple randomized studies have demonstrated equivalent
survival outcomes with mastectomy versus breast conser-
vation therapy (BCT, breast conservation surgery (BCS),
and adjuvant radiation therapy) in the treatment of early
stage breast cancer [1, 2]. In addition, the Oxford meta-
analysis convincingly demonstrated not only a signiﬁcant
local control beneﬁt but also an overall survival beneﬁt with
adjuvantbreastradiationtherapyafterBCS[3].Assuch,BCT
has been established as the standard of care for limited stage
breast cancer oﬀering the advantage of breast preservation,
improved quality of life, and cosmesis. Breast conservation
surgery,exceptinrarecases,isfollowedbyadjuvantradiation
therapy (RT). A typical adjuvant radiation course is 45 to
50Gyin25to28fractions(1.8to2Gyperfraction)delivered
to the whole aﬀected breast. A boost of 10–16Gy in 5 to
8 fractions is usually prescribed to the lumpectomy cavity
for additional local control beneﬁt as demonstrated by two
seminal studies [4, 5].
WiththestandardRTschedule,a5–7weekscommitment
is required. For most patients, this is quite inconvenient
and cumbersome because of employment or social respon-
sibilities, often confounded by remote distance from the
treatment center to their place of work or residence. In
fact, this treatment time commitment has been cited as
one of the main reasons for noncompliance with adjuvant
breast radiation [6]. This demand served as impetus for
the development of abbreviated regimes for whole breast
radiation.
One such schedule is the widely adopted Canadian
fractionation, 42.5Gy in 16 fractions (2.65Gy per fraction)
given over 3 weeks [7]. This and other regimens, 40Gy in 15
fractions and 39Gy in 13 fractions delivered over 3 weeks,
partly borne from its inception, are discussed in detail herein
[7–11].
Conceptually, a shorter course of radiation therapy
necessitates hypofractionation utilizing a higher dose per
fraction to achieve radiobiological equivalent eﬀectiveness
of the standard, more protracted schedule [12]. From
radiobiological principles, since late reacting normal tissues
are more sensitive to increasing dose per fraction, a priori,
larger dose per fraction should yield more long-term toxicity
[12]. Thus, the tenable, reserved position among some
physicians is that the abridged regimens may be “tagged”
with the high clinical price of long-term treatment toxicities.
Thus the lingering question is can we minimize treatment
time without compromising toxicity?
The utilization of hypofractionated whole breast RT
has been contemporaneous with a more focused approach,2 International Journal of Breast Cancer
accelerated partial breast radiation therapy (APBI). As the
name implies, radiation is targeted to the partial breast
only, deﬁned by the lumpectomy cavity borders and up
to a 2cm margin diametrically [13]. This regime employs
several diﬀerent treatment methods to deliver an acceler-
ated hypofractionated course of radiation, with a schedule
ranging from 20Gy administered in 1 fraction as in the
case of intraoperative radiation therapy (IORT) to 38.5Gy
in 3.85Gy fractions twice daily over 5 consecutive days with
external beam radiation.
The underlying principle of partial breast irradiation is
that over 85% of all ipsilateral breast recurrences occur in the
same quadrant within a 1-2cm radius of the index lesion.
By this premise, partial breast RT should not signiﬁcantly
compromise treatment outcomes compared to whole breast
radiation, in low-risk patients [13]. In addition, organs
at risk (OAR) for radiation-induced toxicity such as the
unaﬀectedcontralateralbreast,lungsandheartshouldbeless
threatened by partial breast than with whole breast radiation
therapy.
Partial breast radiation oﬀers a clinically desirable con-
stellation of advantages over conventional radiation, includ-
ing shortened treatment duration and reduction of normal
tissue toxicity. However, this approach inherently assumes
accurate deﬁnition of the lumpectomy cavity. This begs
the question: can we conﬁdently minimize target volume
without compromising treatment outcomes? Image guidance
promises to provide improved accuracy in target localization
that should allow target volume reduction.
Herein, we review the results from the most relevant
hypofractionated whole and partial breast studies and dis-
cuss the implications thereof. We conclude with a brief
discussion of image guidance and its utility in whole and
partial breast radiation.
2. HypofractionatedWhole Breast Irradiation
Several randomized clinical trials have compared the eﬃcacy
ofwholebreastradiotherapywithconventionalfractionation
(i.e., 1.8–2.0Gy fractions) requiring ﬁve to six weeks of daily
treatments versus hypofractionated (i.e., >2Gy fractions)
radiotherapy requiring fewer treatments. Overall, these trials
have shown equivalent local control of breast cancer and
breast cosmesis with conventionally fractionated versus hy-
pofractionated regimens. A Canadian trial compared hypo-
fractionated whole breast regimen delivering a dose of
42.5Gy in 16 fractions of 2.66Gy daily fractions over 22
d a y st oc o n v e n t i o n a lf r a c t i o n a t i o no f5 0 G yi n2 5d a i l y
fractions of 2Gy each [14]. Both regimens were prescribed
without a sequential lumpectomy cavity boost. With median
followup of 12 years, the 10-year local control was 93.3%
versus 93.8% (P>0.05) for the conventional versus hypo-
fractionated radiation, respectively, with both regimens
yielding equivalent cosmesis.
Another trial centered at the Royal Marsden Hospital
compared conventional 50Gy in 2Gy fractions to two
hypofractionated arms, delivering 39Gy or 42.9Gy in thir-
teen 3.0Gy or 3.3Gy fractions, respectively, over 35 days.
That study yielded equivalent 10-year local control rates
of 87.9%, 85.2%, and 90.4% for conventionally fraction-
ated and the two hypofractionated radiotherapy regimens,
respectively [15].
Two additional UK trials, START A and START B (Stan-
dardization of Breast Radiotherapy), with shorter followup
(5-year) similarly demonstrated equivalent local control
between treatment arms [16, 17].
In contrast, an ongoing UK FAST trial (Faster Radiother-
apy for Breast Cancer Radiotherapy) randomized patients
between conventionally fractionated radiotherapy and two
hypofractionated schedules, 28.5Gy in ﬁve 5.7Gy fractions
and 30Gy in ﬁve 6Gy fractions delivered over 35 days. The
results of this trial have not yet been reported in full-text
form [18, 19].
The question of feasibility of delivering lumpectomy
cavity boost after Canadian and other fractionated whole
breast schedules has been posed. Both START and the Royal
Marsden trials prescribed a boost in more than 30% of the
study cohort [15–17]. This has also been addressed by a
single institution Memorial Sloan Kettering Cancer Center
retrospective series in which hypofractionated whole breast
radiation therapy (42.4Gy in 16 fractions of 2.65Gy each)
was delivered to 128 patients followed by a conventionally
fractionated boost of (10Gy in 5 fractions of 2Gy each)
[20]. That study showed comparable cosmetic outcomes
to conventional fraction, and there were no grade 3 or
more toxicities recorded after median followup of 1.5
years. Another large single institution UK series conﬁrmed
feasibility and favorable outcomes with Canadian fraction
followed by boost [21].
In 2010, the American Society for Radiation Oncology
(ASTRO) published evidence-based guidelines for hypofrac-
tionated whole breast radiotherapy [22]. Suitable candi-
dates for hypofractionated radiotherapy are identiﬁed as
women aged ≥50 years with pT1-2 N0 M0 tumors and
who do not receive cytotoxic chemotherapy. With the
latter criterion, there is the advantage of less delay in the
delivery of radiotherapy. It is still uncertain whether all
women beneﬁt equally from hypofractionated as compared
to conventionally fractionated radiotherapy regimens. A
retrospective exploratory subgroup analysis of the Canadian
trial revealed that the hypofractionated regimen was less
eﬀective among women with high-grade tumors (10-year
local recurrence 15.6% versus 4.7%, hypofractionated versus
conventional fractionation regimens, resp.) [14]. Additional
data and continued followup from randomized trials will
be important in determining the long-term eﬃcacy and
cosmesis from hypofractionated whole breast radiotherapy
regimens.
3. Accelerated Partial BreastIrradiation
Accelerated partial breast irradiation (APBI) is another
technique used to deliver a course of radiotherapy over an
even shorter time frame of, usually, 5 days. This regimen
is oﬀered to a select subset of patients [23]. APBI targetsInternational Journal of Breast Cancer 3
the tissue in the periphery of the lumpectomy tumor bed
only. This volume can be targeted with various radiotherapy
techniques such as external beam radiotherapy (either 3-
D conformal, intensity modulated, or electron radiation
therapy), brachytherapy (interstitial or balloon catheter),
and intraoperative radiotherapy (electrons or superﬁcial
photons). Several randomized clinical trials comparing
whole breast to accelerated partial breast irradiation are
ongoing. The NSABP B-39/RTOG 0413 trial, goal accrual of
4300, randomizes patients between whole breast irradiation
or accelerated partial breast irradiation (with choice of either
high-dose rate interstitial brachytherapy, MammoSite bal-
loon catheter, or 3D conformal external bream radiotherapy
technique) to a dose of 34Gy or 38.5Gy in 3.4Gy or 3.85Gy
fractions over 5–10 days. Final results of this trial have not
yet been reported.
The largest reported APBI trial to date, TARGIT (Tar-
geted Intraoperative Radiotherapy) trial, randomized 2232
women (excluding patients with certain high-risk clinico-
pathologic features) between whole breast irradiation and a
single dose of 20Gy with intraoperative radiotherapy with
superﬁcial low-energy photons. At 4 years, there was no
diﬀerence in local control between the whole breast (99.1%)
and partial breast (98.8%) arms [24].
Results employing Electron Intraoperative Therapy
(ELIOT) in 1822 women with early stage breast cancer have
been published, demonstrating 97.7% local recurrence rate
at 3 years and a 5- and ten-year survivals of 97.4 and 89.7%,
respectively, while oﬀering reduction of normal tissues to
radiation exposure [25].
GEC-ESTRO (Groupe Europ´ een de Curieth´ erapie—
European Society for Therapeutic Radiology and Oncology);
RAPID (Randomized Trial of Accelerated Partial Breast Irra-
diation); IMPORT LOW (Intensity Modulated and Partial
Organ Radiotherapy) are examples of current randomized
trials evaluating accelerated partial breast radiotherapy ver-
sus whole breast irradiation in the treatment of low-risk
breast cancer.
The treatment and cosmetic outcomes of mature and
ongoingclinicaltrialsshouldhelptoclarifytreatmentcriteria
and appropriately stratify patients to partial breast versus
whole breast irradiation.
4. ExternalBeam Radiotherapy for Breast
Cancer Using Image Guidance
Image guided radiotherapy (IGRT) involves the use of
localizationtechniquesatthetimeofdailytreatmenttoverify
accurate positioning. The goal of this endeavor is to reduce
patientsetupvariation,inordertofacilitatetheuseofsmaller
margins around target volumes to be used. Smaller margins
should translate into signiﬁcantly smaller volume of normal
tissue radiated which should in turn reduce acute and late
normal tissue toxicity.
In the case of breast cancer treatment, this approach
may reduce late eﬀects to the breast tissue, heart, and
lungs. Used in conjunction with localization of the target
volume, particularly in the case of partial breast irradiation,
IGRT may additively improve daily target dose coverage and
therefore improve local control outcomes as well. Even in
the setting of whole breast treatment, the use of IGRT may
facilitatesmallermarginsaswellasadvancedtechniquessuch
as simultaneous integrated boost and intensity-modulated
radiation therapy (IMRT), both of which require a much
higher degree of setup certainty to be eﬀectively used in
treatment [26, 27].
Aligning to bony anatomy, as is done in MV and KV or
cone beam CT imaging, improves setup accuracy compared
to the traditionally employed surface tattoos [28, 29]. Using
either breast surface or location of intraparenchymal surgical
clipsimproveslocalizationoverstrictlybonyalignment,even
whenusingCTguidance[30].Still,thereissomeuncertainty
associated with the delineation of the tumor bed target
volume because of signiﬁcant interobserver variability [31,
32]. For example, the Radiation Therapy Oncology Group
(RTOG) conducted a multi-institutional interobserver study
among nine radiation oncologists specializing in breast
cancer,todeterminethedegreeofvariabilityintargetvolume
and organs at risk delineation among three sample cases
[33]. They found structure mean overlap of only 72% for
t h el u m p e c t o m yc a v i t yi no n ec a s ea n dp o o ra g r e e m e n t
on nodal structures, with percent overlap as low as 10%
among diﬀerent observers [33]. This variation resulted
in substantial variations in treatment planning and dose
coverage. Consequently, the RTOG has published an atlas of
breast, chest wall, nodal regions, and organs at risk to guide
a more consistent reproducible approach to contouring [34].
We have recently reported our experience at Moﬃtt
Cancer Center using ﬁducial-based IGRT in prospective
cohort of both whole breast and partial breast patients. We
used textured gold ﬁducial markers, which adheres to the
surrounding soft tissue, increasing the likelihood of ﬁducial
stability and consistent visualization. In fact, 100% ﬁducial
visualizationonMVimagingandminimalvariation,wewere
able to verify ﬁducial migration [35].
In the partial breast cohort, there was minimal motion
due to intrafraction motion from respiration or changes in
respiratory motion between 4D CT scans at the time of
simulation to the end of treatment [35]. The mean change
in distance between ﬁducials inter- and intrafraction had a
small range 2 to 3mm, well within the range of error of the
total size of the ﬁducial. Fiducial markers position was stable
during treatment with no evidence of substantial ﬁducial
migration within a 5mm range. The position of the center
of ﬁducial mass relative to the center of the seroma was also
stable,conﬁrming the stability and applicability and textured
ﬁducials in IGRT in the setting of APBI [35].
Similarly, in the whole breast cohort, small ranges in
inter- and intrafraction motion, respiratory motion, and
ﬁducial migration were observed [36]. Our data suggest that,
with ﬁducial-based image guidance, the PTV margin may
be safely reduced from the more standard 10mm to about
5mm, substantially reducing the volume of normal tissue
irradiated unnecessarily. Other investigators using surgical
clipsorﬁducialsforbreastcancerradiotherapyhavereported
similar results [37–41].4 International Journal of Breast Cancer
5. Newer Techniques for Breast IGRT
Although online cone beam CT (CBCT) allows much more
accurate and reproducible alignment in 3 dimensions to
the bony anatomy as compared to surface tattoos or port
ﬁlms alignment, pretreatment CBCT does not guarantee
accurate intrafraction delivery [42, 43]. Prolonged treatment
times and couch rotation can signiﬁcantly reduce treatment
delivery accuracy [44]. To address this confounder, patient
surface setup systems and real time tracking systems have
been recently explored. Data suggest that surface imaging
may oﬀer more precise setup than laser or tattoo with
a similar reduction in error as ﬁducial-based IGRT [45].
Ultrasound systems for localization and tracking of the
tumor bed for daily treatment have also been investigated
andhaveshowngoodcorrelationbetweentheposition ofthe
tumor bed on 3D ultrasound and CT, forecasting the utility
of 3D US in the near future [46]. Similarly, implantable
electromagnetic transponder ﬁducials have been used to
t r a c kb r e a s tt u m o rb e dm o t i o ni nr e a lt i m e[ 47]. With the
rising concern of cumulative radiation doses with multiple
CT imaging and the lifetime risk of secondary cancers,
modalities such as 3D ultrasound image guidance may oﬀer
an attractive alternative.
6. Conclusions
Hypofractionated breast radiation therapy oﬀers the attrac-
tive alternative of shorter treatment course which is not
only convenient for patients, but also time and cost-eﬀective.
The overarching question remains, can we minimize with-
out compromise? Results of randomized and large single-
institution studies seem to support the edict that attaining
this desirable balance is indeed possible.
Reducing target volume, as in the case of external beam
APBI techniques, calls for more reﬁnement of treatment
deliverywithimage-guidedradiationtherapytoensureaccu-
rate delivery of high-dose radiation while sparing normal
tissue such as heart and lungs.
Various methods of performing IGRT, including
implanted ﬁducials,CBCT, surfacemapping, andultrasound
aﬀord measurable improvement in setup error allowing for
PTVmarginreductionstoasmuchas5mm.Eachinstitution
should apply the optimal IGRT technology for their clinical
practice commensurate with the center’s equipment
availability, physician, and technician experience. For, whole
breast radiation, wherein a larger volume of heart and lung
is irradiated, there is a compelling argument to incorporate
IGRT in our daily set up, to achieve optimal results with
minimal toxicity. For accelerated partial breast irradiation in
particular, IGRT should be systematically incorporated into
our daily treatment algorithm.
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